Israel Akinrotimi Akinola

Israel Akinrotimi Akinola

Auto-generated profile, based on publicly available information

Israel Akinrotimi Akinola

Pennington Biomedical Research Center

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2026 in European Journal of Biology
Verified
Journal Article
Closed access
DBDoofan Bur
Doofan Bur
IAIsrael Akinrotimi Akinola
Israel Akinrotimi Akinola
AAAdebisi Abiodun Adeleke
Adebisi Abiodun Adeleke
EEEmmanuel Kennedy Ezika
Emmanuel Kennedy Ezika
KEKelechi Purity Ezennubia
Kelechi Purity Ezennubia
ARAdekunle Rowaiye
Adekunle Rowaiye
To disassemble the mechanisms of action of antipathogenic probiotics from Lactobacillus and Bifidobacterium genera, specifically competitive exclusion, bacteriocin production, short-chain fatty acid release, and immune modulation, to inform the development of microbiome-sparing compounds for multidrug-resistant infections. We conducted a systematic literature search across PubMed, Web of Science, Medline, and Google Scholar, identifying 104 pertinent articles published between 2018 and 2025. These studies were analysed to elucidate the antimicrobial mechanisms of probiotic-derived molecules and their potential for drug development. The analysis of 104 articles revealed that probiotic-derived molecules, including bacteriocins and short-chain fatty acids, create an adaptive anti-pathogen toolkit through competitive exclusion and immune modulation. These mechanisms effectively target MDR pathogens. However, translation to clinical settings remains complex due to inconsistent trial results and highly strain-specific therapeutic effects, underscoring the need for careful validation. Understanding the structural determinants of probiotic-derived molecules could enable the rational design of microbiome-compatible antivirulence drugs and bacteriocin mimetics that neutralise pathogens without harming the commensal microbiota. Harnessing these insights may extend the lifespan of existing antibiotics while advancing sustainable, ecosystem-friendly therapeutics for the post-antibiotic era.